Sodium Pertechnetate Tc 99m

(Technetium Tc-99m Sodium Pertechnetate)

Phase 1

Sodium Pertechnetate Tc 99m is one of 4 small molecule programs targeting Metastatic Endometrial Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Metastatic Endometrial CarcinomaActive, not recruiting

Metastatic Endometrial CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Metastatic Endometrial Carcinoma

#DrugCompanyPhaseTrials

Ruxolitinib XR

Incyte

Phase 1

1 2

Sodium Pertechnetate Tc 99m

Sun Pharmaceutical Industries, Inc.

Phase 1

1 3

Ruxolitinib Phosphate

MMayo Clinic

Phase 1

1 4

Technetium (99mtc) Sestamibi

MMayo Clinic

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Metastatic Endometrial Carcinoma

NCT03120624

Clinical

Trials by Indication[1]

Metastatic Endometrial Carcinoma1 trial

Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer

Active, not recruiting·MMayo Clinic·Phase 1·NCT03120624·34 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 31, 1981

SODIUM PERTECHNETATE TC 99M

NDA NDA017471

Dec 31, 1981

SODIUM PERTECHNETATE TC 99M

NDA NDA017725

Dec 31, 1981

SODIUM PERTECHNETATE TC 99M

NDA NDA017321

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Technetium Tc-99m Sodium Pertechnetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Technetium Tc-99m Sodium Pertechnetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Technetium Tc-99m Sodium Pertechnetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA017471). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Sun Pharmaceutical Industries, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Sun Pharmaceutical Industries, Inc.

Sodium Pertechnetate Tc 99m

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Metastatic Endometrial Carcinoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News